Literature DB >> 19224501

Abnormalities in glucose homeostasis in acromegaly. Does the prevalence of glucose intolerance depend on the level of activity of the disease and the duration of the symptoms?

Maria Stelmachowska-Banaś1, Piotr Zdunowski, Wojciech Zgliczyński.   

Abstract

INTRODUCTION: Acromegaly is characterized not only by disabling symptoms, but also by relevant co-morbidities. Insulin resistance, leading to glucose intolerance is one of the most important contributory factors to the cardiovascular mortality in acromegaly.
MATERIAL AND METHODS: We analysed the records of 220 naïve patients with acromegaly diagnosed at our Department in the years 1995-2007. Diagnosis of active acromegaly was established on the basis of widely recognized criteria. In each patient glucose and insulin concentrations were assessed when fasting and during the 75 g OGTT.
RESULTS: Normoglycaemia existed in 46% of acromegalic patients. Among glucose tolerance abnormalities we found impaired fasting glucose in 19%, impaired glucose tolerance in 15% and overt diabetes mellitus in 20%. There was no statistically significant differences in gender, duration of the disease, basal plasma GH, IGF-1 or fasting insulin concentrations between normoglycaemic patients and those with impairments in glucose tolerance. The groups showed statistically significant differences with respect to age at diagnosis (p < 0.01). There was no significant correlation between GH, IGF-1 concentrations and fasting plasma glucose. There was no correlation between the duration of the disease and fasting plasma glucose. We found a statistically significant correlation between plasma GH, IGF-1 concentrations and HOMA, QUICKI and insulinAUC.
CONCLUSIONS: The prevalence of diabetes mellitus among acromegalics is much higher than in the general population. The occurrence of glucose tolerance impairments does not depend on the duration of the disease. In patients with acromegaly insulin resistance and hyperinsulinemia are positively correlated with the level of activity of the disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19224501

Source DB:  PubMed          Journal:  Endokrynol Pol        ISSN: 0423-104X            Impact factor:   1.582


  10 in total

1.  Preoperative octreotide therapy and surgery in acromegaly: associations between glucose homeostasis and treatment response.

Authors:  R Helseth; S M Carlsen; J Bollerslev; J Svartberg; M Øksnes; S Skeie; S L Fougner
Journal:  Endocrine       Date:  2015-07-16       Impact factor: 3.633

Review 2.  The changing face of acromegaly--advances in diagnosis and treatment.

Authors:  Antônio Ribeiro-Oliveira; Ariel Barkan
Journal:  Nat Rev Endocrinol       Date:  2012-06-26       Impact factor: 43.330

3.  Glucose status in patients with acromegaly receiving primary treatment with the somatostatin analog lanreotide.

Authors:  Elisabeth Couture; Vanina Bongard; Jean-Christophe Maiza; Antoine Bennet; Philippe Caron
Journal:  Pituitary       Date:  2012-12       Impact factor: 4.107

4.  Clinical and biochemical characteristics of acromegalic patients with different abnormalities in glucose metabolism.

Authors:  Ana Laura Espinosa-de-los-Monteros; Baldomero González; Guadalupe Vargas; Ernesto Sosa; Moisés Mercado
Journal:  Pituitary       Date:  2011-09       Impact factor: 4.107

5.  Prevalence and risk factors of impaired glucose tolerance and diabetes mellitus at diagnosis of acromegaly: a study in 148 patients.

Authors:  Orsalia Alexopoulou; Marie Bex; Peter Kamenicky; Augustine Bessomo Mvoula; Philippe Chanson; Dominique Maiter
Journal:  Pituitary       Date:  2014-02       Impact factor: 4.107

6.  HOMA-IR in acromegaly: a systematic review and meta-analysis.

Authors:  Betina Biagetti; Anna Aulinas; Anna Casteras; Santiago Pérez-Hoyos; Rafael Simó
Journal:  Pituitary       Date:  2020-10-21       Impact factor: 4.107

7.  The ability of β-cells to compensate for insulin resistance is restored with a reduction in excess growth hormone in Korean acromegalic patients.

Authors:  Soo Kyoung Kim; Sunghwan Suh; Ji In Lee; Kyu Yeon Hur; Jae Hoon Chung; Moon-Kyu Lee; Yong-Ki Min; Jae Hyeon Kim; Jong-Hyun Kim; Kwang-Won Kim
Journal:  J Korean Med Sci       Date:  2012-01-27       Impact factor: 2.153

8.  Real-world experience with pasireotide-LAR in resistant acromegaly: a single center 1-year observation.

Authors:  Maria Stelmachowska-Banaś; Izabella Czajka-Oraniec; Agnieszka Tomasik; Wojciech Zgliczyński
Journal:  Pituitary       Date:  2021-09-08       Impact factor: 4.107

9.  Prevalence of diabetes mellitus in patients with acromegaly.

Authors:  A V Dreval; I V Trigolosova; I V Misnikova; Y A Kovalyova; R S Tishenina; I A Barsukov; A V Vinogradova; B H R Wolffenbuttel
Journal:  Endocr Connect       Date:  2014-04-29       Impact factor: 3.335

Review 10.  Acromegaly: Clinical Care in Central and Eastern Europe, Israel, and Kazakhstan.

Authors:  Marek Bolanowski; Zaina Adnan; Mirjana Doknic; Mykola Guk; Václav Hána; Irena Ilovayskaya; Darko Kastelan; Tomaz Kocjan; Martin Kužma; Akmaral Nurbekova; Catalina Poiana; Nikolette Szücs; Silvia Vandeva; Roy Gomez; Sorin Paidac; Damien Simoneau; Ilan Shimon
Journal:  Front Endocrinol (Lausanne)       Date:  2022-02-22       Impact factor: 5.555

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.